Comparative Pharmacology
Head-to-head clinical analysis: EMVERM versus VERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMVERM versus VERMOX.
EMVERM vs VERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mebendazole binds to tubulin, inhibiting microtubule polymerization, which disrupts glucose uptake and causes energy depletion leading to parasite death.
Binds to β-tubulin in parasitic cells, inhibiting microtubule polymerization, thereby impairing glucose uptake and causing energy depletion and parasite death.
Mebendazole 100 mg orally twice daily for 3 days for adults and children over 2 years.
Mebendazole 100 mg orally twice daily for 3 days for pinworm, whipworm, hookworm, and roundworm infections. For pinworm, may repeat after 2 weeks. For hookworm and whipworm, may require longer courses.
None Documented
None Documented
2-8 hours; clinical context: the short half-life supports once-daily dosing; metabolites may persist longer.
2-8 hours (terminal half-life, may be prolonged in hepatic impairment or obstruction)
Primarily fecal (approx. 90%) as unchanged drug and metabolites; <10% excreted renally.
Fecal (90%) as unchanged drug and metabolites; renal (<10%)
Category C
Category C
Anthelmintic
Anthelmintic